Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer-Reference-Cited by-同舟云学术

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer

Published:2020-05-31 Issue:8 Volume:14 Page:1881-1897
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Mazzu Ying Z.¹^ORCID,Armenia Joshua²,Nandakumar Subhiksha²,Chakraborty Goutam¹,Yoshikawa Yuki¹,Jehane Lina E.¹,Lee Gwo‐Shu Mary³,Atiq Mohammad¹,Khan Nabeela¹,Schultz Nikolaus²⁴⁵,Kantoff Philip W.¹

Affiliation:

1. Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA

2. Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY USA

3. Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA

4. Marie‐Josée and Henry R. Kravis Center for Molecular Oncology Memorial Sloan Kettering Cancer Center New York NY USA

5. Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York NY USA

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12706

Reference52 articles.

1. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer

2. Novel therapeutic strategies for androgen-independent prostate cancer: An update

3. Prostate cancer

4. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

5. Expression signatures that correlated with Gleason score and relapse in prostate cancer

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GINS2 promotes the progression of human HNSCC by altering RRM2 expression;Cancer Biomarkers;2024-07-01

2. Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer;European Journal of Medicinal Chemistry;2024-04

3. iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer;Translational Medicine Communications;2024-01-19

4. Development of a ferroptosis-based molecular markers for predicting RFS in prostate cancer patients;Scientific Reports;2023-12-20

5. Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients;Discover Oncology;2023-12-19